奥沙利铂联合替吉奥治疗晚期胃癌的效果分析

Analysis on the Effect of Oxaliplatin Combined with Tegafur Gimeracil Oteracil Potassium in the Treatment of Advanced Gastric Cancer

目的探讨晚期胃癌采用奥沙利铂联合替吉奥治疗的效果。方法随机选取我院2014年5月至2015年12月期间收治的50例晚期胃癌患者,分为两组各25例。对照组采用奥沙利铂、亚叶酸钙和5-氟尿嘧啶治疗,观察组采用奥沙利铂联合替吉奥治疗,比较两组患者的治疗有效率、疾病控制率及不良反应。结果在治疗有效率上,观察组为52%,对照组为32%,差异具有统计学意义(P<0.05);在疾病控制率上,观察组为76%,对照组为52%,差异具有统计学意义(P<0.05)。在不良反应方面,观察组的血小板减少、恶心呕吐与肝肾功能异常发生率均显著低于对照组,差异具有统计学意义(均P<0.05)。结论奥沙利铂联合替吉奥治疗晚期胃癌可显著提高治疗有效率和疾病控制率,降低不良反应发生率,具有更好的临床疗效和更高的安全性。

Objective To explore the effect of oxaliplatin combined with tegafur gimeracil oteracil potassium in the treatment of advanced gastric cancer. Methods 50 cases of patients with advanced gastric cancer in our hospital from May 2014 to December 2015 were randomly selected, and divided into two groups, with 25 cases in each group. The control group was treated with oxaliplatin, leucovorin and 5-fluorouracil, while the observation group was treated with oxaliplatin combined with tegafur gimeracil oteracil potassium. The effective rate of treatment, disease control rate, and adverse reactions were compared between two groups. Results The effective rate of treatment of observation group was 52%, significantly higher than 32% of control group （P 〈0.05）. The disease control rate of observation group was 76%, significantly higher than 52% of control group （P 〈0.05）. The incidences of thrombocytopenia, nausea / vomiting and liver / renal insufficiency of observation group were significantly lower than those of control group （P 〈0.05）. Conclusions Oxaliplatin combined with tegafur gimeracil oteracil potassium has better clinical efficacy and higher safety in the treatment of advanced gastric cancer, which can significantly improve the effective rate of treatment and disease control rate, and reduce the incidence of adverse reactions.